MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium ProgramShimin Hu, Ken H. Young, Youli Zu et al.|Blood|2013Cited by 677
CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program StudyShimin Hu, Ken H. Young, Zijun Y. Xu‐Monette et al.|Blood|2013Cited by 246
Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapyWei Wang, Shimin Hu, Jörge E. Cortes et al.|Blood|2016Cited by 191
Stage, age, and EBV status impact outcomes of plasmablastic lymphoma patients: a clinicopathologic analysis of 61 patientsSanam Loghavi, Joseph D. Khoury, Khaled Alayed et al.|Journal of Hematology & Oncology|2015Cited by 139
Cytogenetic risk stratification of 417 patients with chronic myelomonocytic leukemia from a single institutionGuilin Tang, Sa A. Wang, Liping Zhang et al.|American Journal of Hematology|2014Cited by 83